UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER

Signify Bio secured an oversubscribed $15 million initial financing round led by Actium Group with participation from Gates Foundation Strategic Investment Fund, Danaher Ventures, Eli Lilly, and American Cancer Society's BrightEdge.

• Actinium Pharmaceuticals has enrolled the first patient in a pioneering trial evaluating Iomab-ACT as a targeted radiotherapy conditioning agent with commercial CAR-T therapy, with initial data expected in late 2025. • Iomab-ACT targets CD45 on immune cells and has shown promise in reducing serious CAR-T toxicities including ICANS and CRS, potentially addressing major barriers to CAR-T therapy access and efficacy. • The therapy could significantly expand the $4 billion CAR-T market by replacing conventional chemotherapy conditioning regimens, potentially benefiting approximately 150,000 patients diagnosed annually with eligible conditions.

The American Heart Association has funded seven research projects with $1 million to identify which patients with obesity and cardiovascular disease benefit most from GLP-1/GIP medications.

ImPact Biotech will present updated preliminary results from the ENLIGHTED Phase 3 study evaluating Padeliporfin VTP as a non-invasive treatment option for low-grade upper tract urothelial cancer at AUA 2025.

Immunovia's VERIFI study demonstrated 77% detection accuracy for stage I and II pancreatic cancer in high-risk patients, marking the second successful clinical validation of their blood-based diagnostic test.

Cagent Vascular initiates POINT FORCE Registry, a multicenter study across 30 U.S. centers to evaluate their Serranator® PTA Serration Balloon Catheter in treating peripheral artery disease.

Screening for HCC in patients with risk factors is associated with reduced mortality, emphasizing the importance of early detection.

A multicenter study assessed the real-world outcomes of ipilimumab and nivolumab in mesothelioma patients, comparing them to the CheckMate 743 clinical trial.

• Tenaya Therapeutics' lead candidate TN-201, an AAV9-based gene therapy targeting MYBPC3, is being developed for treating hypertrophic cardiomyopathy with projected annual revenues of $165 million by 2038. • The novel gene therapy utilizes adeno-associated virus serotype 9 vectors for intravenous delivery of the cardiac myosin-binding protein-C gene, representing a potential breakthrough in cardiac disease treatment. • Despite operating losses of $131.2 million in FY2023, Tenaya continues advancing its diverse cardiovascular pipeline, including treatments for various forms of cardiomyopathy and heart failure.